毒扁豆胺 | 6091-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 毒扁豆胺
• 英文名称: (-)-eseramine
• 英文别名: 3a,8-dimethyl-5-methylcarbamoyloxy-3,3a,8,8a-tetrahydro-2H-pyrrolo[2,3-b]indole-1-carboxylic acid methylamide；(3aS)-3a,8-dimethyl-1-methylcarbamoyl-5-methylcarbamoyloxy-(3ar,8ac)-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indole；(3aS)-3a,8-Dimethyl-1-methylcarbamoyl-5-methylcarbamoyloxy-(3ar,8ac)-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indol；Eseramin；Eseramine；[(3aS,8bS)-4,8b-dimethyl-3-(methylcarbamoyl)-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
• CAS: 6091-57-2
• 化学式: C₁₆H₂₂N₄O₃
• 分子量: 318.376
• InChiKey: PYEMNABYODPRPP-BBRMVZONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-methoxy-8-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole 在 palladium dihydroxide 甲醇 、 氢气 、 sodium 、 三溴化硼 、 potassium carbonate 作用下， 以 甲醇 、 乙醚 、 乙腈 为溶剂， 反应 3.61h， 生成 毒扁豆胺
  参考文献：
  名称：

  （-）-N1-norphysostigmine，（-）-eseramine和（-）-physostigmine的其他N（1）-取代类似物的合成和抗胆碱酯酶活性。

  摘要：

  （-）-N1-苄基正卟啉（4），由合成（-）-O-甲基-N1-正甾烷（1）通过N-苄基化，醚裂解和（-）-N1-苄基正甾烷（3）与异氰酸甲酯是用于制备标题化合物的中间体。4与5的异氰酸甲酯反应，得到4的催化脱苄基作用，得到（-）-N1-norphysostigmine（5）和（-）-eseramine（6）。5的还原性N-甲基化得到（-）-毒扁豆碱（9），而5与烯丙基溴和苯乙基溴的反应分别得到氨基甲酸酯7和8。据报道有关这些化合物作为电鳗乙酰胆碱酯酶抑制剂的体外效力（IC50）和活性的数据。发现（-）-N1-Norphysostigmine（5）与（-）-physostigmine（9）类似，对AChE的功效也很强。

  DOI：

  10.1021/jm00120a008

文献信息

• Topical macqui berry formula
  申请人：Tracie Martyn International, Inc.

  公开号：US10993897B2

  公开（公告）日：2021-05-04

  The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a photostabilizing agent, encapsulation, or light—and/or air-blocking packaging.

  本发明提供了一种外用制剂和使用方法，其中的制剂包含具有极高氧自由基吸收能力（ORAC）的马奎莓或含有花青素的马奎莓提取物。本发明的制剂提供了稳定形式的马奎莓，其中包括葡萄糖醛酸或糖醛酸、光稳定剂、封装或阻光和/或阻气包装。
• YU, QIAN-SHENG;ATACK, JOHN R.;RAPOPORT, STANLEY I.;BROSSI, ARNOLD, J. MED. CHEM., 31,(1988) N 12, C. 2297-2300
  作者：YU, QIAN-SHENG、ATACK, JOHN R.、RAPOPORT, STANLEY I.、BROSSI, ARNOLD

  DOI：——

  日期：——
• Topical compositions comprising benfotiamine and pyridoxamine
  申请人：Morariu Marius

  公开号：US20060045896A1

  公开（公告）日：2006-03-02

  The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).
• Topical macqui berry formulation
  申请人：Morariu Marius

  公开号：US20070065396A1

  公开（公告）日：2007-03-22

  The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a photostabilizing agent, encapsulation, or light -and/or air-blocking packaging.
• METHODS OF USING BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS
  申请人：Morariu Marius

  公开号：US20100151061A1

  公开（公告）日：2010-06-17

  The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).